Pharma BD Deal Intelligence
A regulatory remedy purchase, not a strategic bet — BI kept the vaccine brands ~7 years then folded them into a bigger $885M exit to Elanco as its own FTC price for buying Merial; the original Fort Dodge, Iowa plant was shuttered within 2 years.
Full analysis, sources & comparables →Pfizer announced on September 21, 2009 the divestiture covered "cattle and small animal vaccines," "animal health pharmaceuticals," "research and manufacturing…
The FTC consent order required Pfizer 'to sell approximately half of Wyeth's Fort Dodge U.S. animal health business to Boehringer Ingelheim Vetmedica, Inc.,…
Pfizer completed its acquisition of Wyeth on October 15, 2009 following approval from all required government authorities; FTC conditions required divestiture…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
FTC-mandated divestiture: ~half of Wyeth's Fort Dodge US animal health business (cattle/dog/cat vaccines, horse vaccines) divested as condition of Pfizer-Wyeth merger. Source: FTC, Pfizer press.
A regulatory remedy purchase, not a strategic bet — BI kept the vaccine brands ~7 years then folded them into a bigger $885M exit to Elanco as its own FTC price for buying Merial; the original Fort Dodge, Iowa plant was shuttered within 2 years.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim Vetmedica, Inc. / Wyeth/Fort Dodge Animal Health (divested assets) (this deal) | 2009 | — | 61 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| QIAGEN N.V. / DxS Ltd. | 2009 | $130M | 85 |
| Sigma-Tau Group / Enzon Pharmaceuticals (Specialty Pharma business) | 2009 | $327M | 85 |
← Browse all deals · How we score deals
More: 2009 deals